3F8 Stock Overview
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.15 |
| 52 Week High | kr0.82 |
| 52 Week Low | kr0.13 |
| Beta | 1.1 |
| 1 Month Change | 6.00% |
| 3 Month Change | -21.65% |
| 1 Year Change | -50.16% |
| 3 Year Change | -99.02% |
| 5 Year Change | -97.42% |
| Change since IPO | -97.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3F8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -26.9% | 0.003% | 1.8% |
| 1Y | -50.2% | -8.3% | 4.2% |
Return vs Industry: 3F8 underperformed the German Medical Equipment industry which returned -10.1% over the past year.
Return vs Market: 3F8 underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| 3F8 volatility | |
|---|---|
| 3F8 Average Weekly Movement | 26.2% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3F8's share price has been volatile over the past 3 months.
Volatility Over Time: 3F8's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 127 | Stuart Gander | qlinea.com |
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. It offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. The company serves healthcare providers.
Q-linea AB (publ) Fundamentals Summary
| 3F8 fundamental statistics | |
|---|---|
| Market cap | €23.56m |
| Earnings (TTM) | -€19.64m |
| Revenue (TTM) | €473.68k |
49.7x
P/S Ratio-1.2x
P/E RatioIs 3F8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3F8 income statement (TTM) | |
|---|---|
| Revenue | kr5.53m |
| Cost of Revenue | kr3.45m |
| Gross Profit | kr2.09m |
| Other Expenses | kr231.45m |
| Earnings | -kr229.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 37.74% |
| Net Profit Margin | -4,145.42% |
| Debt/Equity Ratio | 0% |
How did 3F8 perform over the long term?
See historical performance and comparison